Quest Diagnostics, eMed Team Up To Offer COVID-19 Rapid Antigen Testing At Workplaces

Comments
Loading...
  • Telehealth company eMed and Quest Diagnostics Inc DGX have collaborated for clinician-guided rapid antigen testing for COVID-19 in workplaces.
  • Through the collaboration, the two companies will leverage the BinaxNOW COVID-19 Ag Card Home Test, a self-administered nasal swab antigen test that provides results in 15 minutes.
  • An eMed Certified Guide will virtually supervise the testing process, confirm employee identity, oversee proper sample collection, and authenticate results during a telehealth visit.
  • Individuals will receive their validated results via a digital health pass on their smart device, and employers will have access to a portal with consolidated employee test results.
  • Price Action: DGX shares are up 0.16% at $148.81 during the market session on the last check Wednesday.
DGX Logo
DGXQuest Diagnostics Inc
$167.410.60%

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score
Edge Rankings
Momentum84.64
Growth80.99
Quality25.28
Value26.73
Price Trend
Short
Medium
Long
Market News and Data brought to you by Benzinga APIs

Posted In: